2017

The Pistoia Alliance AbVance Project hits a key milestone

Friday, November 10, 2017

The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has announced that its project to increase knowledge of antibody (Ab) structures has reached its first major milestone—12 antibody structures have been deposited into the European Bioinformatics Institute’s (EMBL-EBI) Protein Data Bank (PDB). The goals of the project are to generate novel Ab structures and improve Ab structural data sharing across the life sciences. This will increase researchers’ predictive power and their ability to accurately model Ab structures; considerably reducing the time and cost associated with generating experimental data to support decision-making in drug projects.

[Read More]

Report: Electronic Trial Master File (eTMF) Market to Touch $190M by 2027

Wednesday, November 8, 2017

Future Market Insights has analyzed numerous aspects of the electronic trial master file (eTMF) market and has included actionable insights in a systematic manner in its new research publication titled, “Electronic Trial Master File (eTMF) Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027).” The extensive research study on eTMF market portrays various facets of the global market such as trends, opportunities, value chain analysis, competitive landscape, drivers, restraints, regional analysis along with key recommendations that can be considered by the reader to achieve his/her strategic objectives in the long run. The research study also covers future market projections with respect to value for a period of ten years starting from 2017 till 2027. The comprehensive analysis on each segment and sub segment of the global market portrays a real time picture of the global market scenario.

[Read More]

Study: Impact of digital health grows, mobile health apps accelerate

Wednesday, November 8, 2017

The impact of Digital Health on patient care is accelerating with the increasing adoption of mobile health apps and wearable sensors. Health-related mobile applications available to consumers now surpass 318,500—nearly double the number available just two years ago—with approximately 200 new apps added to the market each day. This rapid app expansion, coupled with more than 340 consumer wearable devices on the market worldwide, and 571 published efficacy studies, provide evidence of Digital Health’s accelerating innovation and generation of a subset of proven tools to impact human health, according to a new report released today by the IQVIA Institute for Human Data Science.

[Read More]

Chesapeake IRB, Schulman IRB merge to create Advarra

Wednesday, November 8, 2017

Chesapeake IRB and Schulman IRB, two respected institutional review boards (IRBs), have combined to create Advarra, a premier provider of IRB, institutional biosafety committee (IBC) and research compliance services in North America. The new organization will leverage mutual strengths in technology, regulatory expertise and customer service to serve the increasingly complex needs associated with research.

[Read More]

Merck, CDRD partner on Canadian life sciences ecosystem

Monday, November 6, 2017

The Canadian scientific community gathered in Ottawa this week to engage in a national dialogue on science, technology and innovation policy at the annual Canadian Science Policy Conference. Just prior to the Keynote Address at this event by the Honorable Kirsty Duncan, Minister of Science, Merck Canada and CDRD (The Centre for Drug Research and Development) announced the establishment of a new $1.5M Merck-CDRD Innovation Fund. This fund will go directly towards the advancement of projects of high therapeutic potential carried out at CDRD in collaboration with academic researchers.

[Read More]

Wave Life Sciences initiates Duchenne muscular dystrophy clinical trial

Monday, November 6, 2017

Wave Life Sciences, a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced the initiation of a global phase I clinical trial for WVE-210201 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. This clinical trial marks the next stage in the company’s ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company’s third clinical trial initiated in 2017.

[Read More]